Uniquity Bio is a clinical-stage drug development company focused on immunology and inflammation. It is emerging from stealth with an FDA acceptance of its Phase 2 IND for solrikitug, a monoclonal antibody targeting TSLP that was in-licensed from Merck. The company plans to launch Phase 2 clinical trials in COPD and asthma in the coming month and intends to advance solrikitug across respiratory and gastrointestinal indications. Blackstone Life Sciences has committed up to $300 million in capital to advance the asset and support expansion of Uniquity’s immunology and inflammation pipeline. Leadership includes CEO Brian Lortie and Executive Chairman Stephen Tullman, and the company was founded by industry executives with extensive track records in developing and commercializing therapeutics. Uniquity says it will pair global pharma-level scientific rigor with biotech agility and pursue partnerships with leading pharmaceutical companies.

Total raised

$300M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024